1-855-378-42281-855-378-4228
One of the out-patient rehabilitation options for clients in Eastport struggling with opioid dependence and addiction is opioid maintenance therapy. Licensed facilities and doctors are authorized to give specific medications to opioid dependent people, many that are opioid-based also and are addictive. With low enough doses the individual does not experience high feelings and also does not have severe cravings and is not in opioid withdrawal. Methadone is the first medication used for this sole purpose, but there are alternative options to pick from.
Methadone is an opiate and is meant to be taken at an outpatient medical center licensed to administer the drug, which is taken on a daily basis in liquid or pill form. The price of the drug is around one hundred and fifty dolloars a month. Buprenorphine is also an opioid-based med, and is in pill form often taken every other day. But different from Methadone that is only be given in highly structured medical centers, Buprenorphine can be prescribed and dispensed in doctor's offices. The cost monthly of buprenorphine is about three hundred dollars a month for the generic version of the drug. There is also a type of buprenorphine containing the drug naloxone, which is a drug that reverses the effects of opioids. Someone taking this version of the drug, AKA Suboxone, would find it more difficult to get high from opioids if they relapsed while taking the drug. It is also taken daily, and costs about $450 monthly. Naltrexone is an additional medication taken in opioid maintenance therapy, but unlike the other medications mentioned here it's an opioid blocker and is not an opiate. There is an option to take this medication as a monthly injection, which is called Vivitrol. As an opioid blocker, the drug prevents a person from experience being high from opioids, and therefore lowers the risk associated with relapse. This daily shot costs in the range of $1000 to $1200 monthly.
For All Alcohol and Drug Treatment Facilities In Eastport, Click Here.
